Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – ...

Alumis Inc. announced new Phase 3 data showing that investigational envudeucitinib rapidly and durably improved scalp psoriasis, itching and quality of life in patients with moder ...

The real-life findings showed that treatment with brodalumab improved health-related quality of life (HRQOL) for patients but itching prevented complete improvement. Despite achieving clear or almost ...

You notice a scaly, itchy rash on your skin and immediately start wondering what’s causing it. Two common culprits that can look surprisingly similar are psoriasis and ringworm, but getting the right ...

Ustekinumab offers superior itch relief compared to guselkumab in severe psoriasis, despite guselkumab's better skin lesion improvement. The study involved 108 patients, with 90.4% of ...

Skin issues can have a serious impact on your health and well-being. For the 7.5 million Americans living with psoriasis, itch can be the most bothersome part of their condition because it can make it ...

Johnson & Johnson ( JNJ ), a healthcare company focused on innovative medicines and medical technologies, reported two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE (icotrokinra) in ...

A common fatty acid found in the Western diet breaks down into compounds that contribute to increased temperature and pain—but not itch—sensitivity in people with psoriasis lesions, researchers report ...

Please provide your email address to receive an email when new articles are posted on . Arcutis Biotherapeutics announced positive results from two pivotal phase 3 studies evaluating Zoryve cream as a ...